Olaparib Improves PFS in Phase III BRCA-Positive/HER2-Negative Breast Cancer Trial

Olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to recent findings from the phase III OLYMPIAD trial.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.